Page last updated: 2024-09-03

mk 0663 and Rheumatism

mk 0663 has been researched along with Rheumatism in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Micu, MC; Micu, R; Ostensen, M1
Krüger, K1
Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S2
Einecke, D1
Baraf, HS1

Reviews

2 review(s) available for mk 0663 and Rheumatism

ArticleYear
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
    MMW Fortschritte der Medizin, 2005, Aug-04, Volume: 147, Issue:31-32

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etoricoxib; Gout; Humans; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Rheumatic Diseases; Spondylitis, Ankylosing; Sulfonamides; Sulfones

2005
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Current pharmaceutical design, 2007, Volume: 13, Issue:22

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones

2007

Trials

2 trial(s) available for mk 0663 and Rheumatism

ArticleYear
The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Tract; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Pyridines; Rheumatic Diseases; Severity of Illness Index; Sulfones; Treatment Outcome

2006
Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 97, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation Tests; Cross Reactions; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Dyspnea; Etoricoxib; Female; Forced Expiratory Volume; Humans; Male; Peak Expiratory Flow Rate; Pyridines; Rheumatic Diseases; Single-Blind Method; Sulfones

2006

Other Studies

2 other study(ies) available for mk 0663 and Rheumatism

ArticleYear
Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies.
    Arthritis care & research, 2011, Volume: 63, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chi-Square Distribution; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Fertility; Humans; Ibuprofen; Infertility, Female; Inflammation; Norway; Ovarian Follicle; Ovulation; Pregnancy; Prospective Studies; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Sulfones; Ultrasonography

2011
[By what means does the rheumatic patient with gastrointestinal risks fare best?].
    MMW Fortschritte der Medizin, 2007, Mar-08, Volume: 149, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Diseases; Germany; Humans; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Pyridines; Rheumatic Diseases; Risk Factors; Sulfones; United States

2007